Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

Publication Type	Academic Article
Authors	de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis L, Clark C, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis J, Kerkman D, Hampel H, Wahlund L, Davies P
Journal	Neurobiol Aging
Volume	27
Issue	3
Pagination	394-401
Date Published	08/26/2005
ISSN	0197-4580
Keywords	Alzheimer Disease, Amyloid beta-Peptides, Cognition Disorders, Hippocampus, Isoprostanes, Magnetic Resonance Imaging, tau Proteins
Abstract	The diagnosis of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) is limited because it is based on non-specific behavioral and neuroimaging findings. The lesions of Alzheimer's disease: amyloid beta (Abeta) deposits, tau pathology and cellular oxidative damage, affect the hippocampus in the earlier stages causing memory impairment. In a 2-year longitudinal study of MCI patients and normal controls, we examined the hypothesis that cerebrospinal fluid (CSF) markers for these pathological features improve the diagnostic accuracy over memory and magnetic resonance imaging (MRI)-hippocampal volume evaluations. Relative to control, MCI patients showed decreased memory and hippocampal volumes and elevated CSF levels of hyperphosphorylated tau and isoprostane. These two CSF measures consistently improved the diagnostic accuracy over the memory measures and the isoprostane measure incremented the accuracy of the hippocampal volume achieving overall diagnostic accuracies of about 90%. Among MCI patients, over 2 years, longitudinal hippocampal volume losses were closely associated with increasing hyperphosphorylated tau and decreasing amyloid beta-42 levels. These results demonstrate that CSF biomarkers for AD contribute to the characterization of MCI.
DOI	10.1016/j.neurobiolaging.2005.07.003
PubMed ID	16125823